From www.bloodjournal.org by guest on August 21, 2018. For personal use only.
Vitamin
B12-Responsive With
Associated
By Lynnette We
present
blastic
findings
anemia,
that
included
There
was
therapy
and
methylmalonic
normal
but
reactions
in the synthesis
ciency
of
tory
the
that
for
and
by
methylmalonic
two end
products
by
cobalamin-dependent
the
Schuh
and
reflect
The
suggested
to
be
methionine
failure
activity
for at
and
vitro
of
methionine
not
We
patient previously concentration but of culture medium. genetic
the Department Australia; the
Immunology,
Monash
Victoria, rics,
Australia;
Queen
ofllematology. Departments Medical
and
Victoria
Monash
Medical
University Centre,
but to
was to
reducing
April
Presented ogy
Meeting,
New
Supported Research
29.
1986;
accepted
in abstractform by Council
Address
Orleans, from
charge
payment.
“advertisement” indicate this fact. (C) 1987 by Grune
requests
(Blood
National MB.
Hospital
never a very smiled
ofthis
article
This
article
must
accordance
Der
with
were
he had
a febrile
week,
after
therefore /8
U.S.C.
Austra-
in part hereby
Inc.
the
hospital
infant,
symmetrical,
during
spasticity
with
at 59
these
ceased.
21%,
MCV
3.5%,
obvious
increased ethanolamine.
liquid
x 109/L.
homocystine
amino
Bone
acid
and
marrow
increased acid
showed analysis
8.6
a
was
not
Three after anemia
101
fl,
x lOt/L,
neutro-
eosinophils
was markedly
cellular
of the urine serine,
was
not
normal performed
showed
alanine,
leucine,
detected,
organic
MCH
anisocytosis,
71%,
electrophoresis
Methylmalonic
chromatography
was
lymphocytes
High voltage
disturbed,
revealed
hematocrit
719
noted.
truncal
phenobarbitone,
admission
WBC
head
present
seizure.
reticulocytes
were
were
when
g/dL,
and
to
extension
g/dL,
The
and
he developed
given
on
On floppy,
were
7.7
2%. Platelets
marked
reflexes
53.2
and megaloblastic.
solely
g,
a generalized
he was
poikilocytosis.
pale,
4,730
weeks
spine
hypersegmentation,
one
3 cm below the costal nodes not enlarged.
hemoglobin and
about
a
pg, MCHC
1985)
by page
was
35,5
with
time
unsmiling.
with
27%
and
At that
abnormalities
he had
Investigations
the breast
lasting
weight
three and
he was
and he
neurologic
retraction
3,180
that
vomiting
weeks cm,
the subsequent
seizures
Medical Depart-
10
no other
head
macrocytosis
Prahran,
and
weight
stated
six weeks.
unresponsive
height
and
However,
phils
of Hematol-
§1734
diarrhea
who had had
birth from
at about
circumference 39.3 cm. The liver was palpable margin, the spleen not palpable, and lymph Despite his generalized hypotonia, deep tendon
and
acid before
gas
pattern. treatment.
Two weeks after the first dose of vitamin B I 2, no homocysteine was detected in the plasma while methionine was 4 zmol/L (n, 5 to 34). Red cell folate was 1,280 nmol/L of packed cells (n, 230 to 2,200), serum
& Stratton,
to
with
parents
fed successfully
he became
which
Road,
be
illness
which
admission
but
to his parents
of Pediat-
Weyden.
defrayed
baby
responded
developmental
parents
gestation, His
at the age of
and
of unrelated
at birth.
until
and
with
described
was referred
at 38 weeks
condition
responsive
and
Plasma
costs in
Van
Commercial
He was born
followed
66.44a,
Health
infant
newly
hypotonia,
He was the first born losses.
greatly to Dr
0006-4971/87/6904-0028$3.OO/O
1 128
1985
the
another
this
infant,
ofanemia,
further
of Australia.
reprint
publication
Society
for investigation
Prahran,
7, 1986.
American
December
grants
ment ofHematology. Alfred Victoria, 3/81 Australia. The
November
at the
char-
REPORT
male
day
Victoria,
here
characterize
hospital
ha. Submitted
E
may
metabolism.
and on the fifth
Hospital. Department
may
a Caucasian
unresponsive
and
exhibited
assay
Melbourne,
from
cobalamin
anemia and homocystinuria with lymphoblast methionine synthase activity, in contrast to that of the
ofcobalamin
g, and was in good
decreased
which
Alfred
significantly with
described, is independent of assay thiol dependent in part on the cobalamin levels These findings suggest that considerable
heterogeneity
10 weeks
Alfred Hospital. Prahran, of Medicine, Pathology and
School.
reduced
Inc.
CASE
and From Victoria,
cobal-
the
heterogeneity
describe
megaloblastic fibroblast and This reduced
develop-
content
low
conditions.4
regression.
bound
included
at
(thiol)
no fetal
syndrome
synthase,
but
& Stratton,
The patient,
favorably
adenosylCbl
by Grune
Recently
with
cobalamin
findings
not
optimal
man.
this
differ infant
genetic
S 1987
accompa-
homocystinuria
for
mutation.
that
patient’s
increased of
nor-
with
as these
responded
this
patient
described
of both
metabolized
in
reduction
In
are
an infant
basis
of
or
synthesis
normally
who
but
properties
normal
cobalamin,
states
suggest
mutation
obliga-
homocystinuria
anemia,
molecular
methylCbl
unique
and
described
synthase.
fibroblast
11,2 an
reactions
mental delay, megaloblastic not methylmalonic aciduria hydroxoCbl.
to inherited with a defi-
either
latter
intermediates
coworkers3
(meth-
from homocysteine.’
The
and
neonatal reduced activities.
from
consequent
aciduria
acterize
cobal-
synthase
occurs
methylCbl.’
lym-
methylmalonylCoA
uptake of intracellular
cellular
disease
predomi-
These
transcobalamin
to impaired
for
previously
was
but
of the
markedly
characteristics
of our
the
activity
conditions,
culture
with
The
synthase
of
(thiol)
accompanied
medium
adenosylcobalamin
fibroblasts
ofsuccinylCoA
anemia
of activity in
of
synthase
reducing
concentration.
that
meth-
occurs
of methionine
protein
leading
adenosylCbl
by
generation
metabolism
carrier
mediator
mutations nied
catalyzed
megaloblastic
and
(Cbl)
of methionine
of cobalamin
patient’s
levels
that
methionine
of assay
lymphoblasts
Der Weyden
and
reduced
methionine
reduced
of cellular
or methylCbl.
in the
and
Neonatal
by the
cobalamin
Cul-
a
B. Van
reduced
The
Homocystinuria
Activity
Martin
markedly
amin
requirement
proportion
adenosylCbl
methylmalonylCoA
defects
a growth
lymphoblasts
CELLS
(adenosylCbl)
ylCbl)
the
patient’s
as either
mediate
mutase
and
and
development.
and
independent
excretion.
showed
incorporation
normal, in the
nantly
amins
activity
Cobalamin
N HUMAN
neurologic lymphoblasts
Clark,
mal
hematologic
homocystine
C.L.
normal.
seizures.
and
Synthase
were
megalo-
Cyanocobalamin
complete
diminished and
was
ylcobalamin
I
aciduria. by
Arthur
dysfunction tonic
Anemia
Methionine
Sawyer,
neonatal
delay
synthase
methionine.
with
developmental
fibroblasts
phoblasts
infant
neurologic
recovery,
methionine
Margaret
and
subsequently
tured
an
accompanied
neurologic and
J. Hallam,
on
Megaloblastic
Reduced
homocystinuria, no
was
Neonatal
folate
and
renal
tion
showed
41 nmol/L,
function
tests
and were
no abnormality,
Blood,
B12
1 17 pmol/L
normal. and
Cerebral an
EEG
(n,
160 to 500).
ultrasound showed
medium
Liver
examinavoltage
Vol 69. No 4 (April),1987: pp 1128-1133
From www.bloodjournal.org by guest on August 21, 2018. For personal use only.
CONGENITAL
with
METHIONINE
no consistent
SYNTHASE
DEFICIENCY
focal,
or epileptiform
asymmetry, folate
and
antibodies excluded
to intrinsic factor. Transcobalamin II deficiency was by normal findings for patient’s serum mediated 57Couptake elution
after
admission
latter
treatment
as 1,000
peaked
progressive
rise
On treatment
returned
to normal,
no longer
I 2 months.
At
assessment
at
good
3 years
100
progress
born
until
Epstein-Barr
fifth
57Co-
One
folate
and and
toward
the daily.
there
was
of red
cell
normal
Anticonvulsants to I ,000
was
discontinued.
normal
limits
2 years at
her
birth.
At
normal cot the
6 weeks
she
a week
had
A
and
a Hb
12.7
She Post
to estab-
lymphoblasts
from
MATERIALS Cell lines.
Human
individuals
were
(CS
medium
this
(FBS
formed
lymphoblast
mother,
father,
lymphoblast
cell
lines
lines
were
were
(15
maintained
mg/L)
10%
from
the
under
normal
vitamin
Bl2
Kansas
City)
with
indicated
studies
the
appropriate
were
in
with
10%
culture
initiated
at
a cell
l05/mL
respectively
with
counts
performed
using
were
trypan
blue
Fibroblasts Laboratories)
condi-
nmol/L
(5
one
density
of
indicated
as the
2 x
culture
index
at
added
at
growth
l03/mL
and
medium
5 x
conditions,
described with
37#{176}C and
assays.
Lymphoblasts
as described,
centrifuged
Enzyme harvested
0.25%
trypsin
subsequent
washed
ofcells
were
thrice
with
in appropriate
performed
by either
Cell
at 4#{176}C and
supernatant
bovine
(Flow
inactivation
serum
of
determined
THF
Kamely
(5-MTHF) in a total
buffer
pH 7.4 (Ajax
methionine
volume
(BDI-I
(SAM)
method
minor
standard
of0.2
mL:
130
Chemicals,
(Boehringer
of Lowry
was
pH
reaction
mmol/L
Australia), Australia),
Mannheim,
Intact
reaction
cell
cellular
but
assayed was
mixtures
assays.
routinely
also
with
under
determined nitrogen,
Incorporation
synthase
cobalamin
of
aerobic
anaerobically which
were
then
into
acid
l4C-5MTHF
activity
in patient
metabolism
in
‘s cells.
the
patient
and
acetic
control
acid.
from
lymphoblasts
Incorporation
l4C-propionate
yITHF defect
was
by patient’s
cells
normal,
that
was of
by trichloroof radioactivity from
14C
meth-
was significantly reduced (Table 1), suggesting a of methionine synthesis without an abnormality in the
function of methylmalonylCoA ties of enzymes of patient’s I .4
cells
of radioactivity TH F into protein
precipitated but
Altered
patient’s
explored by determining the incorporation from l4C-labeled propionate and methyl
synthesis,
nmol/hour/mg
mutase. lymphoblasts
namely
protein
The that
thymidylate
(mean,
level of activiare involved in synthase,
SE)
serine
6.5
±
hydroxyme-
thyltransferase 257 ± 61 nmol/hour/mg protein, or that of 5,10 methylene THF reductase 2.3 ± 0.3 nmol/hour/mg protein were comparable to the corresponding values of those activities in control lymphoblasts: I .8 ± 0.2 nmol/hour/mg protein. measured
by the
14C-5 mixture
was methyl con-
phosphate B-mercap-
.tmol/L
of
in
patient
and
6.7 ± 0.6, Methionine
control
cell
386 ± 36, and synthase was
extracts
with
and
Table
1 . Incorporation Into TCA
of 1 4C-Propionate
Precipitable
Material
and 1 4C-MethylTHF
of Control
and Patient’s
Lymphoblasts 14C-propionate’ 100 imol/L; 14 iCi4imol
Cells
1 4C-methylTHFt 25 imol/L; 25 iCi/mol
measured
sodium
Germany),
that
material was performed according to the method of Mellman et al’2 and incorporation of l4C-propionate (Amersham, England) into acid precipitable material was as described by Willard et al.’3 Incorporation of 57CO-cyanocobalamin (Amersham) 0.1 ng/mL was performed at two hours and 72 hours as described by Mellman et al’4 and for fractionation of intracellular cobalamin cells were extracted according to the method of Linnell et al’5 and cobalamins separated on a SP Sephadex C-25 column (Pharmacia, Sweden) in the dark, as previously described.4
and
200 mmol/L 275
was
7.4
Activity from
of MeCbl
the incubation.
et al.7
measured
modifications.”
The
the
during
was
above
using
reductase’#{176}were
synthase
dark.
Chemicals,
Extracts
HCL
was determined
of I4C-methionine
in the
tamed toethanol
formation
(PBS). Tris
hydroxymethyltransferaset
Methionine et al with
by the
Protein
(THF)
tetrahydrofolate described.
at 4#{176}C,
in liquid nitrogen or by 1,500 g for 10 minutes
by the
serine
flushing
sealed
at
for assay.
as standard
synthase,t
5,lO-methylene
thawing
were
I 0 minutes
10 mmol/L
centrifuged
used
albumin
as previously
method
were
fibroblasts
g for saline
usually
freeze
extracts
Thymidylate
confluent
phosphate-buffered buffers,
sonication.
or
at I ,000
by
synthase
as described
thymidylate
at 96 hours
of viability.6
by treatment
minute
acid
lymphoblast
as previously
harvested
for
and
FBS.
with
and
the
exclusion
were
or amino
Fibroblast
and
cell
vitamin
concentration.
Methionine
Methionine All
growth
3.7
omission
RESULTS
zg/L). In experiments with modifications of concentration of vitamm B12, folate, or methionine in the culture medium, cells were grown in a modified RPMI 1640 medium (K-C Laboratories, the
protein.
patient,
supplemented
the
fetal
previously.5
in exponential
and
with
EBV-trans-
as described
Laboratories)
normal
essential
with
established
of methionine
mmol/L
and
Australia).
individuals
(Flow
patient
minimum
Australia)
Laboratories,
and normal cell
the
Eagle’s
in
Parkville,
Flow
RPMI 1640 medium FBS. The concentration
from
grown
Laboratories,
serum
METHODS
fibroblasts
routinely
bovine
is 0.1
AND
skin
obtained
precipitable
made mortem
Attempts
and activity
the holoenzyme. Incubation was in the dark at 37#{176}C for 60 minutes. The reaction was terminated by adding 0.8 mL of ice-cold water. The mixture was passed through Bio-Rad AG-1X8 columns (BioRad Laboratories, Richmond, CA), and the columns were washed with an additional I .0 mL of water. The radioactivity in the pooled effluent was determined in a liquid scintillation counter. Enzymespecific activities are expressed as nmol of product formed/hour/mg conditions
modalities.
at 9 weeks.
of death.
(EBV)-transformed
at
physically
morphology.
death
cause
discontin-
in all
was
cell
were twice
Developmental
She
red
sudden
to reveal virus
later.
g
(MeCbl) (Sigma Chemicals, St Louis), 500 mol/ L DL-homocysteine (Sigma Chemicals, St Louis), prepared just before use from the thiolactone derivative, 600 smol/L (14C) 5-MTHF 2 MCi/mol (Amersham, England) and 150 to 160 zg of cell extract. The assay control was minus the addition of MeCbl and methylcobalamin
SAM,
week
B12,
(IM)
day,
no
were not successful.
individual
tions
the return
acid
fI, with
failed
both
reduced
is within
was
examination
on and
folic
normal
MCV
serum
intramuscularly
23%
B I 2 was
2 years
hematologically g/dL,
with
in his urine.
and
sibling
and
had
his general health improved, his muscle tone and there were no further seizures. Homocystine
detected
ued at six months,
lish
at
she
gel chromatography.
begun
in hemoglobin
changes.
female
was
and
lymphoblasts
with
of cyanocobalamin
Reticulocytes
was
by normal pattern
normal,
His
serum
cyanocobalamin
were
features.
mother’s
cyanocobalamin
BI2
1129
S-adenosyl
50 zmol/L
Control
825
±
163
479
±
31
Patient
788
±
190
154
±
26
‘cpm/
106 cells/4
hours.
Value
given
is mean
±
SE for three
separate
determinations. tcpm/ separate
106
cells/24
hours.
determinations.
1:P not significant. §P < 0.01, Student’s
ttest.
Value
given
is mean
±
SE for
seven
From www.bloodjournal.org by guest on August 21, 2018. For personal use only.
Table
2.
Methionine
Patient’s
Synthase
and Control
Activity
in Extracts
Fibroblasts
of Cultured
and Lymphoblasts Specific
2.
Activity’ protein) Holoensyme
Total
(nmol/hotx/mg Enzyme
Control
2.6
±
0.3
0.6
±
0.1
Patient
0.8
± 0.2
0.4
±
0.1
2.7
± 0.2
0.9
±
0.01
±
0.06
Cells
.i
Fibroblastst
2.0
Lymphoblasts Control
p
Mother
1.9
±
0.2
0.8
Father
2.5
±
0.3
1.3 ± 0.04
Patient
0.8
±
0.1
0.4
‘Values
given
are the mean
SE, in excess
±
1.5’
0.03
±
of six separate
I
determina-
tions.
tFibroblasts supplemented assayed
were cultured in Eagle’s minimum essential medium with 1 0% FBS. Cells were harvested upon confluency and
for
methionine
Lymphoblasts 1 0%
were
FBS and
assayed
cells
48
synthase
as
1 640 hours
described
medium
in the
initiation
control
levels
added
total
enzyme
and
lymphoblasts.
was
evident
with
of culture
and
from
cobalamin
up to 96 hours.
no
significant
at
P
Assay
methionine
to
synthase
synthase
that
conditions
under
of control
showed
aerobic
protein
were
2.2
(aerobic)
and
and
2.3
0.6 (anaerobic). Corresponding values for patient lymphoblasts were 0.36 and 0.21 (holoenzyme) nmol/hour/mg protein (aerobic) and 0.40 and 0.30 nmol/hour/mg protein
and
(anaerobic).
In data
not shown,
lymphoblast
extracts
yielded
synthase
activity,
alternatively,
the
excluding
activity
Effect synthase
of alteration ofpatient’s
the
by constituents
of cells.
strated
that
patient normal
with megaloblastic at conventional
methionine
varying
assay
mixing control and patient expected levels of methiopossibility
of patient’s
activation
synthase
methionine
in the
previously
increasing
cell
Effect
described
activities
25
either
mmol/L) and B mercaptoethanol, (7.5 to 200 mmol/L) were determined with lymphoblast extracts of the current patient. In both instances at all concentrations of thiol assayed the
shown
patient’s
fold with
methionine
significantly
synthase those
lower
patient
and
activity
than
control at
the
activities of control
ing conditions
produced nor
a unique
Methionine were
also
with
extracts, concentration
by these interaction
synthase assayed
(Figs 1 and lymphoblasts.
lymphoblast maximal
mmol/L) was approximately four mercaptoethanol (200 mmol/L), equivalent synthase.
(DTT
ofdithiothreitol
times that suggesting thiol of
of patient varying
DTT
are
with
and
control
assay
In
mmol/L.
With
methionine
these
synthase
concentration
addition,
of B
culture
synthase for
in
thiol activ-
of methylcobal-
substitution
and
of
methyl
3.
of
375
used
lymphoblasts
showed
a twofold
and
activity
this
Accumulation of and
and
control
in
methionine
now
distribution culture
of
in the
label
lymphoblasts
(0.5
sg/L, a five-
and the enzyme higher cobalamin
oflabeled
3).
conditions activity,
synthase
normal
levels cul-
(Table
identical
deprivation from
are with
exhibited
comparable under
was
methionine
accumulation
were
with
cultured
nmol/L)
cultured increase
level
cultured
cyanocobalamin
g/L,
on
synthase
or concentration
increase in methionine synthase, hydroxoCbl or cyanoCbl at the concentration
patient
lymphoblasts
lymphoblasts
concentration to 500
methionine
compounds Control
in the
of cobalamin
The
patient
cobalamin
nmol/L
Patient’s
The
concentration
activity.
control
Table
increasing
effect
fibro-
of varying
varying
0.375
neither
methionine
concentrations
the
extracts.
methionine
ture (25
observed with B that the reduc-
reagents DTT
2) were For
methionine of
200
fibroblast
cobalamin by hydroxocobalamin or cyanocobalamin assay system produced no significant differences.
0.2 to
concentrations
and
75
ities were 0. 1 7, 1 .45, and 2.5 nmol/hour/mg protein. Corresponding values for patient fibroblast methionine synthase were 0.04, 0.39, and 0.8 nmol/hour/mg protein. In data not
patient
extracts.
anemia and homocystinuria thiol concentrations. The
5,
control
amin (up to 50-fold), 5-adenosyl methionine (up to fivefold), and 5 methylTHF (up to fivefold) did not significantly alter the reduced methionine synthase activity exhibited by
assay conditions on methionine Rosenblatt et a14 have demon-
synthase
mercaptoethanol: concentrations,
shown,
of inhibition
reduced
of control
Fig 1 . Levels of methionine synthase of patient and control lymphoblasts assayed with varying B mercaptoethanol concentrations. Lymphoblasts were cultured in RPMI 1 640 medium supplemented with 1 0% fetal bovine serum, cells were harvested and assayed for methionine synthase as described in Materials and Methods, with B mercaptoethanol concentration ranging from 7.5 to 200 mmol/L. The values given are the mean of duplicate determinations. , Control; A, patient.
was effect of
blasts
200
mM
conditions.
lymphoblasts
nmol/hour/mg
activity interof patient
at all
synthase
anaerobic
and
fibroblasts
in culture
of methionine under
difference
(holoenzyme)
synthase
150
( 13 Mercaptoethanol)
0.01,
<
holoenzyme
in patient’s
lymphoblasts
lymphoblasts
Methionine
reduced
reduced
This
control
2). Both
(Table
were
in patient’s
and
both
100
50
activity.
different
activities
vals
nine
0.5
text.
supplemented
after
1.0
test.
t
without
activity
in RPMI
harvested
significantly
Student’s
0.9
synthase
cultured
for methionine
Values
or,
ET AL
HALLAM
1 130
range. cobalamin on
cell
and growth.
57Co-cyanocobalamin after
two
hours
in or 24 hours
From www.bloodjournal.org by guest on August 21, 2018. For personal use only.
CONGENITAL
METHIONINE
SYNTHASE
DEFICIENCY
1131
markedly reduced
C
reduced (Table 4). The growth rates when cultured
medium When
or when methionine 2 x l05/mL control
was replaced and patient
plated
in complete
growth
cells
was
9
5
0.2
x
±
z 0 I ‘U.
I05/mL.
105/mL
for the
studied.
Both
initiated E
When
in methionine for
patient 15
ing
(DITHIOTHREITOL)mM
no increase
homocysteine
0.1
x
at 96
culture
3.2
x
was cpm,
l0
patient
19
x
distribution
at
comparable:
control l0
2.4
cpm,
x
control
showed
and
x
cells;
l0
3.
Methionine
Lymphoblasts
Synthase
Cultered
Conditions’
the concentration
and
fibroblasts
Varying
Cobalamin
lymmajor of was
CyanoB
Conditions
12
HydroxoB
12
nmol/L
0.375
3.75
Methionine
187 synthase
375
Control
1.8
2.8(0.8)
8.1
9.0(1.3)
13.0
Patient
0.8
0.9(0.4)
1.7
1.7(0.7)
21
Culture conditionst MethylTHF
1
Methionine
2
HydroxoB
-
synthase
(nmol/hr/mg
4.8
2.1
Patient
1.5
0.6
‘Lymphoblasts with
1 0%
fetal
were calf
hydroxocobalamin
assayed
with
Cells
activity
were
cultured
at
2.tmol/L,
at 48 hours,
described Figures
concentration
RPMI
concentrations
synthase
hydroxocobalamin harvested
in standard varying
as indicated.
for methionine
tLymphoblasts
cultured
serum
were
in RPMI
of
1 640 3.75
and assayed
medium nmol/L
these
disease
genetic
entities
values.
to
0.9
±
lymphoblast
holoenzyme methionine
represent
CbIC
+3
to
enters
+2,
in
Distribu
12
two
different
mutations,
which
tion
include
anemia of our
forma-
not
and
confined
to mdi(I ) were
patient
CN-B12
a
exhibited
content,
and Adenosylc
(2)
obalamin
Extracts Ado-B12
CH3-B12
Cell Line
but
adenosylCbl
and Fibroblast
and
methylma-
disorders,
cobalamin
of Methylcobalamin
S03-B12
occurs
the
mutase
findings neurologic
but
in I ymphoblast
normally
precedes
methylmalonylCoA
Clinical
Cbl
that
and
reduccobalt of
methylCbl. Thus common to of affected cells to accumuand methylCbl and reduced
accumulating
methyl
4.
of
cell
of megaloblastic mutation.’ Cells
CbIC
defective
decreased
least
CbID
event
the
homocystinuria,
incidence with
complementation
at
and
an
into
activities synthase.’
aciduria,
not
genetic
an assumed defect in Cob(lll)alamin activity reduces the charge of the
cobalamin from after cobalamin
OH-B12
% of Total Cobalamin’
Lymphoblast
hours
and
without or with and methylTHF synthase
as
Control
3
2
25
60
7
Patient
4
0
3
87
7
Control
3
0
58
31
8
Patient
3
0
10
76
11
Fibroblast
in the text.
for methionine
control
increased
aciduria-homocystinuria. and
states
termed
both involve tase.’’7 This
‘Results owth balamin
are holoenzyme
methylmalonic
studies,
supplemented at 48
exhibit-
of methionine.
the patient’s x 106/mL.
± 0.1
require-
methionine,
had
and
of cobalamin metabolism resulting in and homocystinuria include the muta-
of biochemical
of cyanocobalamin
harvested
in the text. in parenthesis
1640
as described
defects anemia
protein)
Control
0.4
basis
Table + HydroxoB
was
of congenital the
variable viduals
protein)
for
hours
whereas
hours
Inherited megaloblastic
lonic
375
(nmol/hour/mg
96
x
control
growth
absence
106
0.1
±
lymphoblasts
substituted
at
tion of both adenosylCbl and these mutations is the inability late cobalamin as adenosylCbl
and Control
of
Cobalamin
Added
The
the
of Patient’s
Concentration
Culture
cells.
in human
Activity
Under
hours
was
2.4
the
at 96 x
0.3
±
DISCUSSION
On
24
for fibroblasts
cellular cobalamin is adenosylCbl, but methylCbl in patient’s lymphoblasts Table
patient at
cpm/106
adenosylCbl
in contrast
that
hours
cpm/106
17
of methylCbl
phoblasts
I0
two
Both
in the
also were
Growth 3.2
a preferential
numbers
density
were
and
the patient’s
106 (SEM)/mL,
density
tions in
showed
in cell
lymphoblasts’
was
lymphoblasts
with
was
cultures
x I 06 cells/mL.
lymphoblasts.
for methionine
When
Fig 2. Levels of methionine synthase of patient and control lymphoblasts assayed with varying dithiotreitol concentrations. Lymphoblasts were cultured in RPMI 1 640 medium supplemented with 1 0% fetal bovine serum. and cells were harvested and assayed for methionine synthase as described in Materials and Methods, with dithiothreitol ranging from 0.2 to 25 mmol/L. The values given are the mean of duplicate determinations. #{149}. Control; A. patient.
patient’s
cells
mmol/L)
Lymphoblasts
medium
control
lymphoblasts
ment 10
the
(0.2
lymphoblasts
ofO.5
for control
for the patient’s
media, growth at 96 hours fibroblasts and 3 ± 0.2 x
patient
replete
for
l06/mL
at 96 hours and
fibroblasts. and
at a cell density
hours
by homocysteine. fibroblasts were
homocysteine
patient
control
(SEM)/mL
or
medium,
x l0 (SEM)/mL
± 0.3
substituted for methionine in the was 8 ± 0.5 x 105/mL for control
0 ‘U
patient’s cells exhibited in methionine-replete
tions
expressed
as % of total
for 72 hours
in RPMI
(0. 1 ng/mL).
Values
in duplicate.
1640
cobalamin medium
given are means
in cell extracts
containing
following
57Co-cyanoco-
of two separate
determina-
From www.bloodjournal.org by guest on August 21, 2018. For personal use only.
utilized
the
methyl
group
of methylTHF
normal cells, and (3) incorporated propionate into protein at normal patient
exhibited
megaloblastic
less effectively
than
the radio label from rates. In addition,
anemia
with
patient’s
B12
on
magnitude increased
homocystinuria
and
activity,
serum
l4C our
it is of some
presentation
of increase cobalamin
that exhibited by control activity achieved by the cells
grown
the differing
This finding homocystinuria
may
characteristics
cally, the reduced patient’s lymphoblasts with
optimal
reducing
B-mercaptoethanol.
In
of
suggest activity
of
previously
the
addition,
either
normal
Specifi-
on
described
pletely
or
with
at the
patient
with
as
locus
congenital
homocystinuria and abnormal methionine synthase activity,3 only genetic complementation studies will resolve this question. That this altered methionine synthase is of significance for intact cells is suggested by the reduced methylCbl content
of the
impaired
patient’s
growth
when
rate
methionine
the
cell
absence
cells
of patient
was
fibroblasts
fibroblasts
substituted
of extracellular
is generated
methionine
and
and
in
methionine,
in human
synthase
cells
or
methylthio-containing
by
from
either
portion
this
activity
of
activity
to the
culture cobalamin the patient’s and activity.
these
An
cells
and
by
defects
homocysteine from
the a
cellular
pool.
increase
in
the
differing methionine
concentration
of
added to the culture medium was accompanied increase in this activity of control lymphoblasts with
a twofold
identical medium
change
for
patient’s
cells
changes
decreased
pattern
anemia,
of vitamin
pernicious
anemia
syndromes
are
B12
such
CbIE
homocystin-
or the infants
their
II acquired
of vegan
accompanying
by
of the described
as transcobalamin
mutation
the
characterized
for mutant
activity exhibited and developmental metabolism on the some comment.
in breast-fed
mothers,5’22
of
concentra-
characterization As the two
disorders now
enzyme
difference
and hypothesis. megaloblastic
and
in
of response
to cobalamin
altered methionine synthase features, including seizures impact of altered cobalamin neurologic system deserves CblC,
this
in vivo.
or
neurologic
diversity
if one
sets
aside the background of failure to thrive, listlessness, and irritability. Possibly the specific neurologic syndromes depend primarily on the developmental stage of the infant at the onset of vitamin deficiency. Whatever the manifesta-
Changing effects for synthase
our
is associated
nition
with
a favorable
outcome
as illustrated
in
patient.
cobalamin by a fivefold compared
cultured
conditions. Limiting cobalamin was accompanied by greater degrees
a fundamental
in hereditary
that
activity
tions, failure to diagnose the specific defect and to institute appropriate therapy can have dire consequences for the infant’s ultimate neurologic status,22’24 whereas early recog-
contribution
methionine
it is feasible
reduced
with
suggests
neonatal
for cobalamin.
cells is not entirely clear. It is and probably reflects stabi-
synthase
with
uria, and neurologic delay, the developing
with than
since both the responded com-
cobalamin-related
methionine
patients
Whether
and
cobalamin
Only purification will satisfy this
deficiency,
relative
conditions produced control lymphoblasts’
in culture
in
methylthioadenosine,
the
tion
the
synthase was less
conditions
is so, the differing
activity. enzyme
In
acid
byproduct of polyamine metabolism.20’2’ Methionine for cell growth is potentially a summation of the contributions of these two pathways. The differing growth capacity of our patient’s cells in culture when methionine has been replaced by homocysteine reflects in part the reduced methionine synthase
patient’s
by
amino
by
If this
the
medium
of reactions
of
an
for
patient’s
the absolute level of of the same order as in
of the
basis
our
Although
significance anemia
of cyanoCbl,
augmentation
of enzyme
turnover.”
in methionineevolving.’8”9
this
a series
and
lymphoblasts
culture
The mechanisms involved growth are controversial and
homocysteine.
dependent
lymphoblasts
standard
synthase ofculture of protein synthesis
lization
methio-
same
lymphoblasts, patient was
under
molecular
that
suboptimal.
have in vivo and megaloblastic
doses
by
methionine independent
Although
altered
to large
is mediated
The
con-
5-adenosylme-
activity.
our patient have a defect
DTT
substrate
or
reduced
the
that may
with
increasing
methylCbl,
effect
no
these findings nine synthase that
conditions,
methylTHF,
had
synthase.
methionine synthase activities of our and fibroblasts were not normalized
assay
centrations thionine
of methionine
interest
was
of patient’s methionine in the culture medium
not methylmalonic aciduria. These findings exclude CbIC or CbID mutations and are identical with those reported for the patient with CbIE disease. At variance are
but
of
ET AL
HALLAM
1132
under
in the culture of reduction of
ACKNOWLEDGMENT
We would the fibroblast continuing ration
like to thank I. Jack and Dr G. Young for establishing and lymphoblast cell lines of the patient and for their help
of the
and
advice
and
Maureen
Cross
for excellent
prepa-
manuscript.
REFERENCES I
.
Rosenberg
metabolism,
LE:
Disorders
in Stanbury
of propionate
JB,
Wyngaarden
MS (eds): The Metabolic Basis York McGraw-Hill, 1983, p 474 2. the
Frater-Schroder relationships
with
of
and JB,
methylmalonate
Goldstein
Inherited
JL,
Disease,
ed
5. New
I984
M: Genetic
patterns
of transcobalamin
congenital
defects.
Mol
II and
Cell
Biochem
56:5,
Schroeder
ML,
Bishop
Schuh
S. Rosenblatt
AJ, Seargeant
LE,
Haworth
DS,
Cooper
JC:
BA,
Homocystinuria
and
anemia responsive to vitamin B12 therapy. An metabolism due to a defect in cobalamin metabolism. 310:686, 4.
5.
megaloblastic
inborn error of N EngI J Med
1984 Rosenblatt
MC, Sweetman
Higginbottom
methylmalonic and
I983 3.
N, Grauer K: Altered vitamin B12 metabolism in fibroblasts from a patient with megaloblastic anemia and homocystinuria due to a new defect in methionine biosynthesis. J Clin Invest 74:2149, zuk
Brown
neurologic
aciduria, abnormalities
in cultured
WL: A syndrome
megaloblastic
in a vitamin
ofa strict vegetarian. 6. Young GJ, Hallam
hydrolase
inactivation
human
T- and
B-lymphoblast.
OH,
Rosebrough
Wi,
and
J Lab Clin
of
anemias
Bl 2-deficient
N EngI J Med 229:317, Li, Jack I, Van Der
infant
S-adenosylhomocysteine
L, Nyhan
homocystinuria,
breast
1978 Weyden purine
fed
MB: toxicity
Med
104:86,
Ri:
Protein
I984 DS,
Cooper
BA,
Pottier
A,
Lue-Shing
H,
Matias-
7. Lowry
Farr
AL,
Randall
From www.bloodjournal.org by guest on August 21, 2018. For personal use only.
CONGENITAL
METHIONINE
measurement
with
the
SYNTHASE
folin
DEFICIENCY
phenol
reagent.
1 133
J Biol
Chem
193:265,
I 6.
I951
sis of
8.
Roberts
D,
modulation
Cancer
Loehr
of thymidylate
Res 31:457,
9.
E: Methotrexate
Taylor
and
synthase
cytosine
activity
arabinoside
in CCRF-CEM
cells.
17.
Weissbach
H:
Radioactive
assay
for serine
.
JW,
D, Littlefield
tetrahydrofolate
homocysteine
thionine
B12
vitamin
cells. Proc NatI 12. and
Acad
Mellman
13.
and
dependent
fibroblasts. Willard
berg LE: Rapid
prenatal
methylmalonate
assay
cultured
14.
using
cells.
I, Willard
Mellman
LE: Cobalamin
coenzymne
fibroblasts.
Evidence
Cbl C cells.
J Biol
I 5.
Linnell
of plasma deficiency.
70:2585,
JC,
for Chem Mackenzie
baby
activity
Cobalamin
in normal AC,
Genet
HF,
Mahoney
32:277, in normal
a processing 254:1
1847,
enzyme
binding and
activity
cobalamins in control subjects J Clin Pathol 22:545, 1969
21
Brain
Aust
human
deficient
in
DM:
Patterns
and in cases ofvitamin
BI 2
tumor
in normal AE,
IS,
Rosenberg
Ann
LE:
deficiencies
cell
.
23. 24. ment
lines.
analy-
Rev
Genet
of
Genetic
comple-
methlymalonyl
CoA
Biochem
Biophys
Res
Commun
5, Kasahara T, Kusumoto K, Hida Y, Takaku F: Methionine dependence
and
malignant
hemopoietic
William-Ashman
244:682, 1969 Backlund PS Wighton damage
HG:
in the biosynthesis
Jr,
cells.
MC,
Smith
RA:
liver.
Manson
the
K, of
Cancer
Res
dietary
role
of 5-adenosyl-
in rat prostate.
Methionine
J Biol
JI, Speed
and
On
of spermidine
in rat
in infancy
Chem
synthesis 256:1533,
I. Robertson vitamin
J Biol
from 1981
E, Chapman
BI 2 deficiency.
E: Med
2:1, 1979 Heaton
due to maternal J, Matthews
Mellman inherited
5’-methylthioadenosine 22.
P. Rosenberg mutant
culture.
1982
Pegg
Chem
Rosen-
1976 and
and biochemical
in cell
1983
growth 20.
mutant
MJ,
LE: Genetic
mutants
Kano Y, Sakamoto K, Ozawa K, Miura
19.
42:3990,
1979
M, Wilson
in human
L-methionine
Youngdahl-Turner
synthesis
quently
Suda
and postnatal detection of inborn errors of and cobalamin metabolism: a sensitive Hum
activity:
me-
kidney
1978
Hart
mutase
cell
LE:
62:952,
LM,
by
hamster
HF, among
117:429,
1973
Rosenberg
enzyme
of 5 methylactivity
in cultured
HF,
Ambani
propionate,
W: Regulation
methyltransferase
J Clin Invest HF,
Erbe
folate
Sci USA
I, Willard
cobalamin
human
reducPediatr
1977
Kamely
Rosenberg
evidence for a new class of human cobalamin mutant. Am J Hum Genet 30:1, 1978 18. Mecham JO, Rowitch D, Wallace CD, Stern PH, Hoffman RM: The metabolic defect of methionine dependence occurs fre-
trans-
Anal Biochem I 3:80, 1985 10. Rosenblatt DS, Erbe RW: Methylenetetrahydrofolate tase in cultured human cells. I . Growth 2. Metabolic studies. I I
Willard
mentation
hydroxymethylase.
Res 11:1137,
WA,
cobalamin
12:223, 1978
1971
RT,
Fenton human
Thomas
D: Another PK,
in hereditary
surg Psychiatry
case
pernicious Hoffbrand
transcobalamin 45:74,
1982
of megaloblastic
anemia. AV,
anemia
of infancy
N EngI J Med 300:202,
1979
Smith
involve-
IS: Neurological
II deficiency.
J Neurol
Neuro-
J
From www.bloodjournal.org by guest on August 21, 2018. For personal use only.
1987 69: 1128-1133
Vitamin B12-responsive neonatal megaloblastic anemia and homocystinuria with associated reduced methionine synthase activity LJ Hallam, M Sawyer, AC Clark and MB Van der Weyden
Updated information and services can be found at: http://www.bloodjournal.org/content/69/4/1128.full.html Articles on similar topics can be found in the following Blood collections Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.